Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) has been assigned an average recommendation of "Hold" from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $43.60.
Several brokerages recently weighed in on MLYS. Zacks Research raised Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, September 11th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating and issued a $56.00 target price on shares of Mineralys Therapeutics in a research report on Monday, October 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Thursday, October 15th. Finally, UBS Group initiated coverage on shares of Mineralys Therapeutics in a research report on Sunday, October 11th. They issued a "neutral" rating and a $29.00 price target on the stock.
Read Our Latest Research Report on MLYS
Insiders Place Their Bets
In related news, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the completion of the sale, the director owned 6,200 shares of the company's stock, valued at approximately $177,196. This trade represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the business's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total transaction of $1,909,500.00. Following the completion of the sale, the chief executive officer owned 528,621 shares of the company's stock, valued at $13,458,690.66. The trade was a 12.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 189,758 shares of company stock valued at $5,209,856. 18.94% of the stock is owned by insiders.
Institutional Investors Weigh In On Mineralys Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of MLYS. BlackRock Inc. acquired a new position in shares of Mineralys Therapeutics during the 2nd quarter worth about $158,832,000. Orbimed Advisors LLC boosted its stake in shares of Mineralys Therapeutics by 109.4% in the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock valued at $55,613,000 after buying an additional 1,072,500 shares during the period. Bank of America Corp DE bought a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at $40,620,000. American Century Companies Inc. grew its holdings in shares of Mineralys Therapeutics by 22.7% during the third quarter. American Century Companies Inc. now owns 1,272,064 shares of the company's stock worth $31,967,000 after purchasing an additional 235,297 shares during the last quarter. Finally, Aberdeen Group plc increased its position in Mineralys Therapeutics by 29.8% in the 3rd quarter. Aberdeen Group plc now owns 894,403 shares of the company's stock valued at $22,476,000 after acquiring an additional 205,168 shares during the period. 84.46% of the stock is owned by institutional investors.
Mineralys Therapeutics Trading Down 3.5%
Shares of MLYS opened at $13.66 on Friday. The stock's fifty day simple moving average is $21.12 and its 200 day simple moving average is $25.75. Mineralys Therapeutics has a twelve month low of $13.57 and a twelve month high of $44.13. The company has a current ratio of 11.83, a quick ratio of 11.83 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.21 billion, a P/E ratio of -3.13 and a beta of 0.83.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.09). On average, equities research analysts forecast that Mineralys Therapeutics will post -4.64 earnings per share for the current year.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.